Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q3 2018 · 10-Q
Revenue$762.00K$762.00K+205.0% vs Q3 2017 Net Income-$532.58K-$532.58KN/M vs Q3 2017 EPS Diluted-$0.02-$0.02— vs Q3 2017 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
-$473,000
N/M
Operating Cash Flowderived-$346,000N/M Free Cash Flowderived-$348,000N/M Margins · derivedGross margin5.1%
Operating margin-62.1%+92.5 pt vs Q3 2017
Net margin-69.9%−25.2 pt vs Q3 2017
ended Dec 31, 2017 · filed Feb 20, 2018 · 51 d after period end